Verona Pharma PLC VRNA.OQ, VRNA.O is expected to show a rise in quarterly revenue when it reports results on April 29 for the period ending March 31 2025
The London United Kingdom-based company is expected to report revenue of $52.712 million, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Verona Pharma PLC is for a loss of 14 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 17.0% in the last three months.
Wall Street's median 12-month price target for Verona Pharma PLC is $76.00, above its last closing price of $64.78.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.20 | -0.29 | -0.40 | Missed | -36.8 |
Sep. 30 2024 | -0.62 | -0.50 | -0.56 | Missed | -12 |
Jun. 30 2024 | -0.37 | -0.29 | -0.88 | Missed | -198.3 |
Mar. 31 2024 | -0.15 | -0.16 | -0.32 | Missed | -95.1 |
Dec. 31 2023 | -0.21 | -0.26 | -0.18 | Beat | 30.8 |
Sep. 30 2023 | -0.30 | -0.28 | -0.18 | Beat | 35.7 |
Jun. 30 2023 | -0.30 | -0.29 | -0.08 | Beat | 72.7 |
Mar. 31 2023 | -0.19 | -0.19 | -0.24 | Missed | -26.3 |
This summary was machine generated April 25 at 13:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。